Document 3098
 DOCN  M94A3098
 TI    Laboratory markers of long-term survivors with HIV disease.
 DT    9412
 AU    Knight B; Salvato P; Thompson C; Houston Immuno. Institute, TX.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):154 (abstract no. PB0041). Unique
       Identifier : AIDSLINE ICA10/94369477
 AB    OBJECTIVE: To describe laboratory markers of HIV disease in long-term
       survivors. METHODS: 174 HIV-seropositive pts. were evaluated
       retrospectively by chart review over a 9-yr. period. 64 pts., HIV+ since
       1985 and whose CD4 count remained > 500 after 9 years, were reviewed.
       Laboratory markers measured in the 9th year were CD4, CD8 counts, p24
       antigen, neopterin, and beta 2 microglobulin. In addition, AZT use was
       assessed. RESULTS: 38 pts. were on AZT (mean 4(1-6) yrs), 26 were not on
       AZT. Mean (mean) CD4 count at the 9th year was 683 (500-1246), mean CD8
       count 1465 (644-2250), mean neopertin level 8 (2-36), and mean beta 2
       microglobulin level 3.2 (1.6-5.2). 12 pts. were p24 positive (1 on AZT,
       11 not on AZT). There were no significant differences in laboratory
       markers between pts. on AZT vs. no AZT except for p24 antigen values.
       CONCLUSIONS: Long-term survivors in this study maintained CD4 counts >
       500 and high CD8 counts over a 9-year period. Neopterin and beta 2
       microglobulin levels remained in the relatively normal range. AZT did
       not seem to alter laboratory markers of disease progression. AZT did
       have an effect on p24 antigen level but this effect did not transulate
       into differences in laboratory markers assessed in this study.
 DE    beta 2-Microglobulin/ANALYSIS  Biological Markers/*BLOOD
       Biopterin/ANALOGS & DERIVATIVES/BLOOD  Comparative Study  CD4-CD8 Ratio
       Follow-Up Studies  Human  HIV Core Protein p24/BLOOD  HIV
       Seropositivity/*BLOOD/DRUG THERAPY/MORTALITY  Predictive Value of Tests
       Prognosis  Retrospective Studies  Survival Rate  Time Factors  T4
       Lymphocytes/*IMMUNOLOGY  Zidovudine/THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).